CB 1 cannabinoid receptor (CB 1 R) undergoes both constitutive and agonist-induced internalization, but the underlying mechanisms of these processes and the role of β-arrestins in the regulation of CB 1 R function are not completely understood. In this study, we followed CB 1 R internalization using confocal microscopy and bioluminescence resonance energy transfer measurements in HeLa and Neuro-2a cells. We found that upon activation CB 1 R binds β-arrestin2 (β-arr2), but not β-arrestin1. Furthermore, both the expression of dominant-negative β-arr2 (β-arr2-V54D) and siRNA-mediated knock-down of β-arr2 impaired the agonist-induced internalization of CB 1 R. In contrast, neither β-arr2-V54D nor β-arr2-specific siRNA had a significant effect on the constitutive internalization of CB 1 R. However, both constitutive and agonist-induced internalization of CB 1 R were impaired by siRNA-mediated depletion of clathrin heavy chain. We conclude that although clathrin is required for both constitutive and agonist-stimulated internalization of CB 1 R, β-arr2 binding is only required for agonist-induced internalization of the receptor suggesting that the molecular mechanisms underlying constitutive and agonist-induced internalization of CB 1 R are different.
Internalization of G protein-coupled receptors (GPCRs) is an important process in the regulation of receptor function. Although its main function is the modulation of receptor number on the cell surface, thereby adjusting the sensitivity of the cell to external stimuli, it also plays role in the resensitization and signaling of GPCRs (Ferguson, 2001; Hunyady and Catt, 2006; Shenoy and Lefkowitz, 2011) . At the molecular level, β-arrestins are key regulatory proteins of receptor internalization, as they can bind to activated GPCRs, as well as to clathrin and the adaptor protein AP-2, thus directing the receptor towards clathrin-mediated endocytosis (Shenoy and Lefkowitz, 2011) . β-arrestins also mediate receptor desensitization, as their binding to the activated GPCRs causes the uncoupling of the receptor from its cognate G protein (Shenoy and Lefkowitz, 2011) . Furthermore, they play important roles in the activation of G proteinindependent signal transduction pathways, e.g. the activation of MAP kinases, phosphatidylinositol 3 kinase, Akt or the small GTP-ase RhoA (DeWire et al., 2007; Wei et al., 2003) .
β-arrestin1 (β-arr1) and β-arrestin2 (β-arr2) are two ubiquitously expressed isoforms of β-arrestins (Ferguson, 2001) . Although β-arrestin binding is a general property of most activated GPCRs, the selectivity and stability of these binding shows receptor specific differences. Namely, class A receptors (e.g. the β 2 adrenergic receptor) bind β-arr2 with a higher affinity than β-arr1, and this binding is transient, i.e. it can only be detected at or near the plasma membrane. In contrast, class B GPCRs, such as the AT 1 angiotensin receptor, bind both β-arr1 and β-arr2 with relatively high affinity and form stable complexes with β-arrestins, so that β-arrestins remain bound to the receptor after internalization and can be detected on intracellular vesicles (Oakley et al., 2000) .
The CB 1 cannabinoid receptor (CB 1 R) belongs to the superfamily of G proteincoupled receptors (GPCRs). The receptor plays role in many important physiological processes, such as learning, thinking, nociception or the regulation of food-intake (Pacher et al., 2006) . Activation of presynaptic CB 1 Rs by postsynaptic endocannabinoid release, which mediates retrograde transmission, is a key regulatory mechanism in the central nervous system, but paracrine activation of CB 1 Rs with a similar mechanism can also occur in extraneural tissues (Freund et al., 2003; Gyombolai et al., 2012; Sanchez et al., 2001; Turu et al., 2009; Szekeres et al., 2012) . The cellular signaling events following CB 1 R activation are mainly associated with the activation of heterotrimeric G i/o -proteins and include inhibition of adenylyl cyclases, activation of K ir channels, inhibition of Ca v channels and phosphorylation and activation of different subtypes of mitogen-activated protein kinases (MAP kinases) (Turu and Hunyady, 2010) . G protein-independent signaling events following CB 1 R stimulation have also been reported (Sanchez et al., 2001 ).
Similar to most GPCRs, CB 1 R internalizes upon agonist stimulation. This has been demonstrated in many cell lines, including CHO (Rinaldi-Carmona et al., 1998) , AtT20 Jin et al., 1999; Roche et al., 1999) , F11 (Coutts et al., 2001) , neuroblastoma N18TG2 (Keren and Sarne, 2003) and HEK293 (Keren and Sarne, 2003; Leterrier et al., 2004) cells, as well as in hippocampal neurons, which naturally express CB 1 R (Coutts et al., 2001; Leterrier et al., 2006) . According to different studies, this agonist-induced CB 1 R endocytosis occurs via clathrin-and/or caveolin-mediated pathways in different cell types (Bari et al., 2008; Hsieh et al., 1999; Keren and Sarne, 2003; Wu et al., 2008) .
Numerous studies suggest that β-arr2 is involved in the regulation of CB 1 R. Coexpression of both GRK3 and β-arr2 was needed for the proper desensitization of the receptor in Xenopus oocyte (Jin et al., 1999) , and dominant negative GRK2 and β-arrestin constructs reduced CB 1 R desensitization in hippocampal neurons (Kouznetsova et al., 2002) . In β-arr2 knockout mice desensitization and downregulation of CB 1 R were impaired in certain regions of the central nervous system (Nguyen et al., 2012) .
Recruitment of β-arr2 to the activated CB 1 R has also been demonstrated (Daigle et al., 2008a) . Mutation of amino acids S426 and S430 was shown to inhibit receptor desensitization as well as late phase receptor endocytosis, but not β-arrestin binding (Daigle et al., 2008b; Jin et al., 1999) . It has been demonstrated that serine and threonine residues at the C-terminus of CB 1 R are involved in its β-arr2 binding and agonist-induced endocytosis (Daigle et al., 2008b; Hsieh et al., 1999) . In contrast to the various studies that clearly point to an interaction between CB 1 R and β-arr2 upon agonist stimulation, no direct data have been hitherto presented concerning the β-arr1 binding of CB 1 R. In some structural studies, the association of β-arr1 with a synthesized CB 1 R C-terminus has been shown (Bakshi et al., 2007; Singh et al., 2011) , however, such binding has not been demonstrated with the intact CB 1 R in living cells.
Constitutive internalization of CB 1 R (i.e. spontaneous internalization in the absence of CB 1 R agonists) has also been detected in hippocampal neurons, as well as in CHO and HEK cells (Leterrier et al., 2004 (Leterrier et al., , 2006 McDonald et al., 2007a; Turu et al., 2007) . It has been suggested that constitutive CB 1 R internalization is the consequence of its basal activity, since inverse agonist treatment or inhibition of basal activity with a DAG lipase inhibitor (e.g. tetrahydrolipstatin) interfered with this process (Leterrier et al., 2004 (Leterrier et al., , 2006 Rinaldi-Carmona et al., 1998; Turu et al., 2007) . However, other studies have concluded that constitutive internalization occurs independently of receptor activity (McDonald et al., 2007a (McDonald et al., , 2007b Kleyer et al., 2012) . The latter statement raises the possibility that constitutive and agonist-induced internalization of CB 1 R may occur via distinct endocytic mechanisms (McDonald et al., 2007a) . However, no evidence has been hitherto presented showing that these two processes are truly different in that they require distinct endocytic machinery to take place.
Our main goal was, considering the important consequences of β-arrestin recruitment in the regulation of cell function, to characterize the β-arrestin binding properties of CB 1 R and to reveal possible differences in constitutive and agonist-driven CB 1 R endocytosis by investigating the role of β-arrestins in these processes.
Materials and Methods

Materials
The cDNAs of the rat vascular CB 1 R and CB 1 R-eYFP were provided by Zsolt Lenkei (Centre National de la Recherche Scientificue, Paris). β-arrestin1, β-arrestin2 and β-arrestin2-eGFP cDNAs were kindly provided by Dr. Marc G. Caron (Duke University, Durham, NC). Molecular biology enzymes were obtained from Fermentas (Vilnius, Lithuania) and Stratagene (La Jolla, CA). pcDNA3.1 vector, coelenterazine h, fetal bovine serum (FBS), OptiMEM, Lipofectamine 2000, and PBS-EDTA were from Invitrogen (Carlsbad, CA). WIN55,212-2 and AM251 were from Tocris (Bristol, UK).
Cell culture dishes and plates for BRET measurements were from Greiner (Kremsmunster, Austria). HaloTag® Alexa Fluor® 488 Ligand was from Promega (Madison, WI). Control siRNA, human β-arrestin2-specific siRNA, mouse β-arrestin2-specific siRNA and clathrin heavy chain-specific siRNA (with sequences 5'-UUCUCCGAACGUGUCACGU-3', 5'-GGACCGCAAAGUGUUUGUG-3', 5'-ACGUCCAUGUCACCAACAA-3' and 5'-GAAAGAAUCUGUAGAGAAA-3', respectively) were from Eurofins MWG Operon (Ebersberg, Germany 
Plasmid constructs and site-directed mutagenesis
The mVenus-tagged rat AT 1a receptor (AT 1 R-mVenus), human β 2 adrenergic receptor (β 2 AR-mVenus) and rat CB 1 R (CB 1 R-mVenus) were created by exchanging the sequence of fluorescent proteins in AT 1 R-YFP (Turu et al., 2006) , β 2 AR-Sluc or CB 1 R-YFP, respectively, to the sequence of mVenus using AgeI and NotI restriction enzymes. The mCherry-tagged AT 1 R (AT 1 R-mCherry) and Cerulean-tagged β 2 AR (β 2 AR-Cerulean) were created similarly. β-arrestin2-Rluc was constructed as described previously (Turu et al., 2006) . β-arrestin1-Rluc and β-arrestin1-GFP were generated from β-arrestin2-Rluc and β-arrestin2-GFP, respectively, by replacing the cDNA of β-arrestin2 (MKTIIALSYIFCLVFA) to achieve proper plasma membrane localization of the final construct (Guan et al., 1992) . This product was inserted into a pEGFP-C1 vector (Clontech, Palo Alto, CA) in the place of eGFP sequence (pHalo-C1 vector). CB 1 R cDNA was then inserted into pHalo-C1 after the HaloTag cDNA to yield Halo-CB 1 R.
CB 1 R-Sluc was generated from CB 1 R-YFP by replacing the eYFP coding sequence with the cDNA of super Renilla luciferase (Woo and von Arnim, 2008) . EYFP-tagged ICAM-1 (ICAM-YFP) was constructed as described previously (Varnai and Balla, 2007) . V54D mutation was inserted into the appropriate β-arrestin2 constructs by the QuikChange® site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer's suggestions. Sequences of all constructs were verified using automated DNA sequencing.
Cell cultures and transfection
HeLa and Neuro-2a cells were maintained in DMEM supplemented with 10% FBS, (Invitrogen, Carlsbad, CA), 100 μg/ml streptomycin, and 100 IU/ml penicillin in 5% CO 2 at 37 °C. 
Bioluminescence resonance energy transfer (BRET) measurements
The BRET assay measuring the effects of different CB 1 R variants on G protein activation was carried out as described previously (Turu et al., 2007) . To measure BRET between β-arrestins and receptors, HeLa cells were transfected with Renilla luciferase-tagged β-arrestin isoforms (β-arr1-Rluc or β-arr2-Rluc) and mVenus-tagged AT 1 R, β 2 AR or CB 1 R, and measurements were performed on the day after transfection. nm excitation and 530 nm emission) by average Rluc bioluminescence counts (measured in non-stimulated cells after the addition of coelenterazine h). This was plotted against the average BRET ratio change measured 3 to 5 min after agonist stimulus. The measurements were done in triplicates, and the BRET records shown here are calculated from at least three independent experiments. BRET change was defined as the BRET ratio of a given time point minus the average BRET ratio of the initial (non-stimulated) time points. BRET change was baseline-corrected to the vehicle curve.
Confocal laser-scanning microscopy
Cells were grown on glass coverslips and transfected with the indicated constructs, as described above, 48 hours prior to measurement. EGFP (or Halo-Alexa488) and mCherry (or RFP) were excited with 488 nm argon, and 543 nm helium/neon lasers, respectively, and emitted fluorescence was detected with 500-550 bandpass and 560 longpass filters, respectively, using a Zeiss LSM 510 confocal laser scanning microscope. For quantification of confocal measurements, 20 images of individual cells were taken from each sample, and intracellular and total cell fluorescence intensities of the images were determined using the ImageJ software (W. S. Rasband, ImageJ, United States National
Institutes of Health, Bethesda, MD (rsb.info.nih.gov/ij/)). Intracellular fluorescence was divided by total cell fluorescence to yield IC/total cell fluorescence ratio. Blind selection and analysis of the cells were performed to avoid any bias during the evaluation of the internalization data.
Halo-labeling protocols
To measure agonist-induced internalization of the receptor, Halo-CB 1 R-transfected cells were stained with Halo-Alexa488 ligand diluted 1:20 000 in DMEM, and incubated at 37°C, 5% CO 2 for 15 minutes. Cells were then washed twice with DMEM to remove unbound Halo-Alexa488, and treated with DMSO, WIN55,212-2 (10 μM) or WIN55,212-2+AM251 (10 μM+30 μM, respectively) at 37°C, 5% CO 2 for 30 minutes.
At the end of stimulation period, cells were washed twice with PBS and fixed with 4%
formaldehyde at 4°C for 15 minutes. Fixed cells were analyzed under confocal microscope as described above.
To measure constitutive internalization of the receptor, Halo-CB 1 R-transfected cells were stained with Halo-Alexa488 ligand diluted 1:20 000 in DMEM, and incubated at 37°C, 5% CO 2 for 15 minutes. Cells were then washed twice with DMEM to remove unbound Halo-Alexa488 and incubated in DMEM at 37°C, 5% CO 2 for 5 hours and 45 minutes without any further treatment or in the presence of DMSO, WIN55,212-2 (10 μM) or AM251 (30 μM). To control the effectiveness of siRNA transfection during the 6 hours of incubation, parallel samples were subjected to the same washing procedures, however, without the staining period at the beginning. For these cells, an 'agonistinduced' protocol (15 min staining + 30 min WIN55 stimulus, see above) was applied 45 minutes before the end of the experiment. At the end of the 6 hours, all cells were washed twice with PBS and fixed with 4% formaldehyde for 15 minutes at 4°C. Fixed cells were analyzed under confocal microscope as described above.
Western blot analysis
Cells for Western blot analysis were transfected on 6-well plates parallel to the cells transfected for confocal analysis. On the day of experiment, cells were placed on ice and washed with ice-cold PBS. Cells were scraped into SDS sample buffer, briefly sonicated, boiled at 95°C for 5 min, centrifuged at 4°C for 10 min and separated on SDS polyacrilamide gels. The proteins were transferred to PVDF membranes, blocked (30 min, 5% fat-free milk powder in PBS with 0.05% Tween 20 (PBST)) and incubated with rabbit anti-β-arrestin2 primary antibody or mouse anti-clathrin heavy chain primary antibody (1 h, diluted 1:1000 or 1:4000, respectively, in PBST containing 5% fat-free milk powder) and HRP-linked goat anti-rabbit or anti-mouse (respectively) secondary antibody (30 min, diluted 1:2000 in PBST containing 5% fat-free milk powder). To control the total protein amount of cell samples, antibodies were removed with standard stripping buffer and a second immunostaining procedure was carried out with mouse anti-β-actin primary antibody (1 h, 1:10 000) and HRP-linked goat anti-mouse secondary antibody (30 min, 1:10 000). The antibodies were visualized using SuperSignal West Pico reagent (Pierce Biotechnology Inc., Rockford, IL), according to manufacturer's instructions. Western blot images were scanned and quantified using the ImageJ software.
Changes in β-actin levels were used to normalize changes in β-arr2 or clathrin heavy chain levels.
Statistical analysis
Statistical analysis was made using the software SigmaStat for Windows 3.5 (Systat Software Inc., Richmond, CA). The effects of co-transfected siRNAs were evaluated using Student's t-test or two-way ANOVA with Holm-Sidak's post-hoc test, as appropriate. Data shown are mean ± SEM values.
Results
β-arrestin binding properties of CB 1 R
β-arrestin binding properties of CB 1 R were first analyzed using a bioluminescence resonance energy transfer (BRET) based approach. BRET was measured between Renilla luciferase tagged β-arr1 or β-arr2 (β-arr1-Rluc and β-arr2-Rluc) and the mVenus-tagged CB 1 R (CB 1 R-mVenus) in transiently transfected HeLa cells. Stimulation using WIN55,212-2 (WIN55, 10 μM), a potent synthetic CB 1 R agonist, led to an increase in the BRET signal when β-arr2-Rluc was co-expressed with CB 1 R-mVenus (Fig. 1A) reflecting the recruitment of the β-arr2-Rluc molecules to CB 1 R-mVenus following receptor activation. In contrast, the same stimulus did not cause any detectable change in the BRET signal between β-arr1-Rluc and CB 1 R-mVenus (Fig. 1A) , indicating that this subtype of β-arrestin does not bind to CB 1 R following receptor activation.
To investigate the β-arrestin binding of CB 1 R more thoroughly, BRET titration experiments were performed. In these experiments, BRET signal is measured and plotted as a function of the BRET acceptor/donor (mVenus/Rluc) expression ratio. In case of a specific interaction, such as the binding between a GPCR and β-arrestins upon agonist stimulus, BRET titration follows a saturation curve, the slope of which corresponds to the affinity between the two BRET partners (Marullo and Bouvier, 2007) . Thus, BRET titration experiments were carried out between CB 1 R-mVenus and β-arr1-Rluc or β-arr2-Rluc. Furthermore, the mVenus-tagged β 2 -adrenoceptor and AT 1 angiotensin receptor (β 2 AR-mVenus and AT 1 R-mVenus, respectively) were also tested for their β-arrestin affinities in the same system, as these two receptors are prototypical class A and class B GPCRs, respectively (Oakley et al., 2000) , and therefore their β-arrestin binding properties could be used as a reference in our experiments. As expected, BRET titration curves of β 2 AR-mVenus and AT 1 R-mVenus followed saturation kinetics with both β-arrestin isoforms after agonist stimulus. While AT 1 R-mVenus binds both isoforms with high affinity (Fig. 1B) , in case of β 2 AR-mVenus, substantial difference was observed between β-arr1-Rluc and β-arr2-Rluc binding, showing that this GPCR has substantially higher affinity for β-arr2 (class A GPCR, Fig. 1C ). BRET titration curve of CB 1 RmVenus and β-arr2-Rluc also followed saturation kinetics, however, with a very low steepness. In contrast, no detectable BRET signal change occurred with β-arr1-Rluc even at high acceptor/donor ratios (Fig. 1D ).
β-arrestin binding of CB 1 R was also visualized using confocal microscopy. In
HeLa cells transiently transfected with mCherry-tagged CB 1 R (CB 1 R-mCherry) and GFP-tagged β-arr1 or β-arr2 (β-arr1-GFP or β-arr2-GFP, respectively), CB 1 R-mCherry was present at the plasma membrane as well as in intracellular vesicles in non-stimulated cells. This distribution corresponds to constitutive internalization of CB 1 R, a well-known property of this receptor ( Fig. 2B and F) . On the other hand, both β-arr1-GFP and β-arr2-GFP showed diffuse cytoplasmic (and, in the case of β-arr1-GFP, also nuclear) localization in non-stimulated cells, without any detectable β-arrestin either at the plasma membrane or in intracellular vesicles ( Fig. 2A and E). After stimulation with WIN55, marked redistribution of β-arr2-GFP could be observed within a few minutes, namely it appeared in punctuate structures at the plasma membrane. However, the inner regions of the cytoplasm showed no accumulation of β-arr2-GFP containing vesicles even after longer periods of stimulation (Fig. 2G) . In contrast to β-arr2-GFP, β-arr1-GFP showed no change in its localization after WIN55 stimulus (Fig. 2C ), indicating that this subtype of β-arrestin does not bind to CB 1 R. In the same system, fluorescently labeled β 2 AR and AT 1 R showed β-arrestin binding pattern, which are in good agreement with their class A and class B behavior, respectively, i.e. β 2 AR bound β-arr1 and β-arr2 only at the plasma membrane (Suppl. Fig. 1A-D) , whereas AT 1 R remained bound with both isoforms in endosomal vesicles (Suppl. Fig. 1E-H) .
The above data indicate that, based on its β-arrestin binding properties, CB 1 R belongs to the class A group of GPCRs, i.e. upon activation, β-arr2 binds to the receptor, but remains bound to it only in the proximity of the plasma membrane, whereas CB 1 R does not recruit β-arr1.
Dominant-negative β-arr2 impairs agonist-induced CB 1 R internalization
Next, the agonist-induced internalization of CB 1 R was investigated. We utilized the Halo labeling technique, as the analysis of the internalization of C-terminally tagged CB 1 R variants using confocal microscopy is difficult because of the presence of the constitutively internalized intracellular receptor population. The HaloTag protein was fused to the N-terminus of the receptor (Halo-CB 1 R). When expressed by the cells,
HaloTag is able to rapidly and covalently bind Halo-Alexa488, its membrane-impermeant fluorescent ligand. Using this method, the receptor population residing in the plasma membrane can be selectively stained, and their internalization can be followed. The functionality of Halo-CB 1 R was tested using BRET assays measuring the G protein activation and the β-arr2 binding of the receptors upon WIN55 stimulus, and no significant difference was detected between the EC 50 (mol/l) values of wild-type and
HaloTag-labeled CB 1 R dose-response curves (pEC 50 8.98±0.22 versus 9.02±0.12 for G protein activation and 6.48±0.14 versus 6.49±0.08 for β-arr2 binding, respectively, n=3).
To study agonist-induced internalization, cells were stained for 15 minutes, treated with vehicle or CB 1 R ligand for 30 minutes, and then fixed and analyzed using confocal microscopy. In vehicle-treated cells, plasma membrane staining was clearly detectable, and labeling of intracellular vesicles was minimal (Fig. 3A) . WIN55 treatment resulted in the appearance of numerous intracellular vesicles, representing intensive agonist-induced internalization, which was inhibited by the CB 1 R inverse agonist AM251 (Fig. 3B-C) . To study the role of β-arr2 in this process, first, a dominant-negative β-arr2 mutant, β-arr2-V54D (β-arr2-V54D) was applied. This mutant has reduced ability to bind to GPCRs Krupnick et al., 1997) , and has been widely used to study the role of β-arr2 in receptor internalization. We co-expressed the RFP-tagged form of wild-type or V54D mutant β-arr2 (β-arr2-RFP and β-arr2-V54D-RFP, respectively) with Halo-CB 1 R. Co-expression of β-arr2-RFP did not impair the WIN55-induced CB 1 R internalization ( Fig. 3D-G) . However, in cells expressing β-arr2-V54D-RFP, agonistinduced internalization of Halo-CB 1 R was markedly reduced (Fig. 3H-K) , suggesting a role for β-arr2 in agonist-induced CB 1 R internalization.
siRNA-mediated knock-down of β-arr2 impairs agonist-induced internalization of CB 1 R
siRNA-mediated knock-down of a protein provides an alternative approach to study its role in a given mechanism. Therefore, the effects of transfection of cells with β-arr2-specific siRNA (β-arr2 siRNA) were also investigated. Western blot analysis showed approximately 50% reduction in β-arr2 protein levels of these cells (Fig. 4A) .
Internalization of Halo-CB 1 R in these experiments was analyzed as described above.
CB 1 R internalization upon WIN55 treatment was intact in cells transfected with control siRNA, but was markedly reduced in β-arr2 siRNA-transfected cells ( Fig. 4B-E) . As the cells that were transfected with siRNA could not be individually identified in these experiments, quantification of the samples was carried out to properly evaluate the effects of siRNA transfection. This showed a significant inhibitory effect of β-arr2 siRNA on agonist-induced CB 1 R internalization (Fig. 4F) .
Agonist-induced internalization of CB 1 R
To investigate the agonist-induced internalization of CB 1 R in a more quantitative way, we monitored the movement of the receptor between the plasma membrane and the cytoplasm, by measuring BRET between the YFP-tagged form of ICAM-1, a plasma membrane resident protein (ICAM-YFP), and the SuperRenilla luciferase-tagged CB 1 R (CB 1 R-Sluc) in transiently transfected HeLa cells. In cells expressing CB 1 R-Sluc and ICAM-YFP, WIN55 stimulus led to a decrease in the BRET signal, indicating the removal of CB 1 R-Sluc from the plasma membrane (Fig. 5A ). This decrease reached its maximum 10 to 20 minutes after stimulation, and showed then no considerable change until the end of the measurement (at approximately 40 minutes after stimulation).
Overexpression of wild-type β-arr2 had no significant effect on CB 1 R internalization.
However, when β-arr2-V54D was co-expressed in the cells, the extent of the BRETdecrease upon WIN55 stimulus was significantly lower than that observed in control cells (Fig. 5A ). The effect of siRNA mediated β-arr2 knock-down on CB 1 R internalization was also studied using the same BRET assay. We found that the knock-down of β-arr2 with β-arr2 siRNA resulted in a marked reduction of BRET signal decrease after CB 1 R activation, reflecting the impaired agonist-induced internalization of the receptor (Fig.   5B ).
These data indicate that β-arr2 binding is required for the agonist-induced internalization of CB 1 R, since interference with this binding following receptor activation, either caused by dominant-negative effect or through the genetic knock-down of β-arr2, results in impairment of agonist-induced CB 1 R internalization.
Constitutive CB 1 R internalization is not affected by β-arr2 impairment
Recent data suggest that constitutive internalization may occur independently of CB 1 R activity (McDonald et al., 2007a (McDonald et al., , 2007b Kleyer et al., 2012) , and since β-arr2 coupling is an activity-dependent process, it raises the possibility that it is a second, differently regulated endocytic process. Therefore we monitored receptor constitutive endocytosis using similar approaches with Halo-tagged CB 1 R to address possible differences in its regulation compared to agonist-induced internalization. In these experiments, cells were stained for 15 minutes with the Alexa488-conjugated Halo-ligand, and incubated for a total of 6 hours in medium to allow spontaneous CB 1 R endocytosis to occur. In control cells, a large number of vesicles could be seen intracellularly, demonstrating constitutive endocytosis of CB 1 R (Fig. 6A ). This could be further enhanced with WIN55 treatment, whereby hardly any detectable receptor was present on the plasma membrane by the end of the 6 hours incubation period (Fig. 6B ). AM251 treatment along the 6 hours had no inhibitory effect on constitutive CB 1 R internalization (Fig. 6C) , showing that this form of internalization is not dependent on receptor activity. When studying the role of β-arr2 in this process, cells co-expressing β-arr2-RFP showed no detectable change in the extent of constitutive internalization ( Fig. 6D-E) . Moreover, in contrast to agonist-induced endocytosis, in cells co-expressing the dominant-negative mutant β-arr2 (β-arr2-V54D-RFP), intracellular Halo-CB 1 R-containing vesicles were still present, in a similar extent as in control or β-arr2-RFP expressing cells (Fig. 6F-G) . When cells were co-transfected with either control or β-arr2 siRNA, no significant difference in the intracellular vs. total cell fluorescence ratio could be detected between these cells after 6 hours of incubation,
showing that constitutive internalization of CB 1 R was not affected (Fig. 7A ). The effect of siRNA was not attenuated throughout the incubation period, as in the same experiments, agonist-induced CB 1 R internalization was still impaired when tested at the end of the incubation period (Fig. 7B ). These data suggest that β-arr2 is not required for the spontaneous internalization of CB 1 R. Similar results were obtained when Halo-CB 1 R internalization was investigated in a Neuro-2a mouse neuroblastoma cell line, which is known to endogenously express CB 1 R (Graham et al., 2006) . siRNA mediated knockdown of β-arr2 (resulting in an approximately 80% reduction of β-arr2 protein levels, Suppl. Fig. 1A ) impaired agonist-induced internalization of Halo-CB 1 R significantly in these cells, but had no effect on the constitutive internalization of the receptor ( Fig. 7C and D). These data indicate that the β-arr2 requirements of CB 1 R internalization are not specific to HeLa cells and are regulated similarly in Neuro-2a cells, which express endogenous CB 1 Rs.
siRNA-mediated knock-down of clathrin heavy chain impairs both agonist-induced and constitutive internalization of CB 1 R
Our results showed that constitutive CB 1 R internalization is independent of β-arr2 binding, which raises the question whether this form of CB 1 R endocytosis is clathrinmediated. Therefore we applied siRNA-mediated knock-down of clathrin heavy chain in HeLa cells, and monitored constitutive endocytosis of Halo-CB 1 R under these conditions, as described above. Western blot analysis showed approximately 50% reduction in clathrin heavy chain levels of these cells (Suppl. Fig. 2B ). We found that in cells transfected with clathrin heavy chain siRNA the spontaneous endocytosis of Halo-CB 1 R over 6 hours was significantly impaired compared to control siRNA-transfected cells (Fig. 8A ). In the same experiments, agonist-induced CB 1 R internalization was also inhibited in clathrin heavy chain siRNA-transfected cells (Fig. 8B) . These results show that, although the β-arr2 requirements for agonist-induced and constitutive CB 1 R internalization are different, both of them occur at least partly by a clathrin-mediated process.
Discussion
Our data show that, based on its β-arrestin binding characteristics, CB 1 R can be classified as a class A GPCR. The relatively low affinity of the binding between CB 1 R and β-arr2 is indicated by the low steepness of slope of the BRET saturation curve between the two molecules upon CB 1 R stimulation, and by the lack of detectable β-arrestin2 in late endosomes after CB 1 R internalization in confocal experiments.
Furthermore, we found in our BRET and confocal measurements that β-arr1 recruitment to the activated CB 1 R is essentially absent. This was not caused by the presence of the fluorescent tag on the C-terminus of CB 1 R because the binding of β-arr2 could be detected using the same receptor construct. The C-terminal tagging of β-arr1 is also not likely to cause the lack of the signal, as both β-arr1-Rluc and β-arr1-GFP constructs could be successfully used to detect β-arr1 recruitment to AT 1 R and β 2 AR. In a previous study, Bakshi et al. have shown using nuclear magnetic resonance (NMR) that a C-terminal fragment of CB 1 R is able to bind β-arr1 (Bakshi et al., 2007) . Our data suggest that such binding between the two molecules, even if present, must be very weak compared to β-arr2, when tested with native proteins in living cells.
According to Oakley and colleagues, the class A or class B behavior of a GPCR is basically determined by the absence or presence (respectively) of multiple serine/threonine-containing clusters at the receptor C-terminus (Oakley et al., 2001) . Our findings demonstrating a class A pattern for CB 1 R are in good agreement with this theory, as the C-terminus of CB 1 R contains only one such cluster (463-SVSTDTS-469) (Oakley et al., 2001 ).
The class A behavior of CB 1 R may have an important impact on the pattern of receptor internalization, de-and resensitization. Furthermore, one should be aware of this property of CB 1 R when studying the signal transduction of the receptor. As mentioned in the introduction, β-arrestin can by itself moderate different intracellular signaling pathways. It was also shown that the localization of β-arrestin-dependent MAPK activation is dependent on the class A/class B characteristics of the involved receptor.
After stimulation of class B receptors, β-arrestin activates a MAPK pool that remains associated with endosomes, whereas in the case of class A GPCRs, the MAPK activated by β-arrestin is able to reach the nucleus (Tohgo et al., 2003) . CB 1 R is also known to mediate ERK phosphorylation, and early gene expression changes are associated with this pathway (Derkinderen et al., 2003; Graham et al., 2006; Valjent et al., 2001 ).
However, G protein-dependent and β-arrestin-dependent MAPK activation of GPCRs are known to be spatially and temporally different (Ahn et al., 2004) . Although the role of β-arrestin molecules in CB 1 R-mediated ERK activation has been suggested (Daigle et al., 2008a) , the exact role of this process in CB 1 R-mediated ERK activation requires additional studies. It is very likely that the class A behavior of CB 1 R is associated with a characteristic distribution of MAPK activation, nevertheless, direct studies that address these questions are needed to confirm them.
Agonist-induced internalization of G protein-coupled receptors is usually the direct consequence of receptor activation. Similarly, constitutive receptor internalization is also generally considered to be a result of constitutive receptor activity. This scenario also implies that the mechanisms that control the endocytosis of a given receptor after agonist activation are similarly engaged in its spontaneous endocytosis. This has also been the prevailing idea in the case of CB 1 R trafficking. In our study, the Halo labeling technique was utilized to analyze the mechanism of internalization of CB 1 R. The cellular trafficking of GPCRs is often followed by the use of fluorescent proteins fused mainly to the C-terminus of the receptor. However, the detailed analysis of the internalization of such receptor variants under microscope is often hindered by the continuously visible intracellular receptor populations (representing either maturing or endosomal receptors), and this is especially true for constitutively internalizing receptors, such as CB 1 R.
Receptor distribution on cell surface and in intracellular vesicles is a function of internalization and recycling rates, representing an actual equilibrium of these processes.
When cells are treated with a receptor antagonist, theoretically both processes can be altered. Receptor internalization can be inhibited by decreasing constitutive activity, or recycling may be altered by targeting the receptor to different intracellular trafficking routes. Thus, measuring C-terminally tagged receptor distribution in cells can be misleading when trafficking of constitutively internalizing receptors is measured.
Furthermore, alterations in the trafficking of C-terminally tagged CB 1 R have been also suggested (Rozenfeld, 2011) . All these difficulties can be overcome by the use of Nterminal tags that can be covalently labeled with small, membrane-impermeable fluorescent ligands. Indeed, such receptor variants (i.e. SNAP and CLIP-tagged receptors) have been utilized in the studying of CB 1 R internalization (Ward et al., 2011a (Ward et al., , 2011b ). Here we used another variant, the HaloTag labeled form of CB 1 R. As indicated in our study, G protein activation and β-arrestin binding of Halo-CB 1 R have not been altered due to the N-terminal labeling, and therefore this receptor can be used to study receptor trafficking with the same advantages as the above mentioned ones.
The main finding of our study is that constitutive CB 1 R internalization is not only independent of the active/inactive state of the receptor, but it occurs via a mechanism which is at least partly different from activity-driven endocytosis.
This finding is based on our observations that agonist-induced CB 1 R internalization requires β-arr2 binding, whereas constitutive internalization of the receptor does not. As described in the introduction, the binding between β-arr2 and CB 1 R as well as a role for β-arrestins in the desensitization of CB 1 R have been demonstrated by former studies (Bakshi et al., 2007; Daigle et al., 2008a Daigle et al., , 2008b Jin et al., 1999; Kouznetsova et al., 2002; Nguyen et al., 2012; Singh et al., 2011) . Therefore, the role of β-arr2 in CB 1 R endocytosis may seem to be a logical consequence of its recruitment to the receptor. However, in fact, none of these studies provided direct evidence at the cellular level that β-arrestin binding is required for CB 1 R internalization. This is important because various examples demonstrate that β-arrestin2 recruitment and receptor internalization can be independent processes, as it is the case e.g. with the PAR1 thrombin receptor (Paing et al., 2002) , the CXCR2 chemokine receptor (Fan et al., 2001; Zhao et al., 2004) , the N-formyl peptide receptor (FPR) (Vines et al., 2003) , or at high agonist concentration the AT 1 angiotensin receptor (Gaborik et al., 2001; Hunyady and Catt, 2006; Zhang et al., 1996) . Therefore, it is important to study directly the β-arrestin dependence of CB 1 R internalization. In the present study we performed these experiments using a dominant-negative β-arrestin2 mutant and siRNA-mediated knockdown of β-arr2. Our data demonstrate that β-arr2 binding is required for the agonistinduced internalization of CB 1 R.
In contrast, using similar approaches, we have demonstrated in our study that, although both agonist-induced and constitutive CB 1 R endocytosis are mediated at least partly by clathrin, constitutive internalization of CB 1 R is a β-arr2-independent process.
Earlier, McDonald et al. raised the idea that these two forms of CB 1 R internalization may occur via different, or at least partly different, pathways (McDonald et al., 2007a) . Our work provides experimental evidence to support their proposal. Such regulatory phenomenon is however not a unique property of CB 1 R, as similar differences in the mechanisms of tonic versus agonist-induced internalization have been demonstrated in the case of other GPCRs, such as the TP thromboxane A2 receptor (Parent et al., 2001) , the Y1 neuropeptide Y receptor (Holliday et al., 2005) or the mGlu 1 metabotropic glutamate receptor (Dale et al., 2001) . Furthermore, we also show here that the spontaneous internalization of CB 1 R is not simply a consequence of its constitutive activity, since it also occurs in the presence of the CB 1 R inverse agonist AM251, i.e.
when the receptors are stabilized in their inactive state. This is in line with the data published by McDonald et al., which showed no alterations in the cellular distribution of CB 1 R upon inverse agonist treatment in neurons (McDonald et al., 2007a) . In contrast, a previous study using inverse agonist treatment (Leterrier et al., 2006) , and our study using DAGL-inhibitor treatment (Turu et al., 2007) have shown an inhibition of basal endocytosis of the receptor upon these treatments, suggesting a role for basal CB 1 R activity in this process. Since active receptors internalize by β-arr2-dependent mechanism, those results may seem to be contradictory with our present results, where we now find that interfering with β-arr2 expression or function does not have effect on constitutive endocytosis. One explanation for these differences is our previous observation that CB 1 R has different basal activity in different cell types used in these studies (data not shown). The other possibility is that inhibition of receptor activity may interfere with intracellular trafficking, so it might also accelerate recycling, thus the rate of activity-dependent constitutive internalization may be well overestimated in those experiments. This is supported by the observation, that in resting cells, β-arr2 is not translocated to the plasma membrane, suggesting a low percent of active receptors there (Fig. 2E ). The advantage of using the Halo technique is that we can now selectively follow trafficking of surface receptors, thus recycling becomes less of an issue.
Therefore, combined with previous results, the data presented here are consistent with a model in which continuous CB 1 R internalization in resting cells is caused to a certain extent by basal release of endocannabinoids, the rate of which may vary in different cell types, while another part of basal CB 1 R internalization is 'truly' constitutive, i.e. it is independent of CB 1 R activation and requires a mechanism that is different from agonistinduced, β-arrestin2-dependent internalization.
Recent work by Kleyer and colleagues demonstrated that in immune cells
expressing endogenous CB 1 Rs, internalization of the receptor is independent of its activation (Kleyer et al., 2012) , suggesting that agonist-dependent internalization may not have physiological role in primary cells. However, in hippocampal neurons, it has been demonstrated that agonist treatment leads to internalization (Coutts et al., 2001) . These data, together with differences detected in the regulation of constitutive internalization (Leterrier et al., 2006; McDonalds et al., 2007a) are in good agreement with our results
showing that CB 1 R internalizes through at least two different mechanisms. Depending on the environment in a particular cell type, or on the methods used by different groups, one or the other mechanism might be more prevalent.
The physiological role of spontaneous CB 1 R endocytosis is not clear at the moment. It has been suggested that constitutive CB 1 R internalization in neurons have a role in the axonal distribution of the receptor (Leterrier et al., 2006; McDonald et al., 2007a) . This underlines the importance of constitutive CB 1 R endocytosis in the central nervous system. However, CB 1 Rs are also expressed in peripheral cannabinoid target tissues, and we have practically no data what is the importance of such trafficking feature of the receptor in these cells. On the other hand, maintained functionality of intracellular CB 1 R populations has been demonstrated (Brailoiu et al., 2011; Rozenfeld and Devi, 2008) , and this raises the idea that the activation of intracellular versus plasma membrane CB 1 R populations may differentially regulate cell functions (Rozenfeld, 2011) .
Nevertheless, additional studies are needed to further clarify the importance of constitutive CB 1 R endocytosis in different body tissues.  CB 1 R binds β-arrestin2 but not β-arrestin1 upon activation.  Agonist-induced internalization of CB 1 R is β-arrestin2 dependent.  Constitutive CB 1 R internalization does not require β-arrestin2.  Agonist-induced and constitutive CB 1 R endocytosis are distinctly regulated processes.
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